Small stature or growth retardation is a frequent problem in children, often leading to serious psychological repercussions. In some patients, as for instance in those with achondroplasia, severe hypothyroidism, or classical Turner's syndrome, the underlying disorder can easily be recognized. More often the growth retarded child presents no other symptoms, and the cause of dwarfism remains obscure in spite of a good history and a careful physical examination. A few years ago, many of these children were treated with anabolic steroids without further investigation. Most of them respond to anabolic steroids with an impressive spurt of growth, but bone maturation is likely to be more accelerated than growth, resulting in a decrease rather than the intended increase in the final height attained. Now hope has turned from the anabolic steroids to growth hormone (GH) which in contrast to anabolic steroids stimulates growth rather than bone maturation.
GH shows a remarkable species specificity in chemical structure and biological activity. In man only human GH (HGH) is effective. The structure of HGH has recently been elucidated (Li, Liu, and Dixon, 1966 (Soyka, Ziskind, and Crawford, 1964; Mason and Tanner, 1967 (Landon, James, and Stoker, 1965; Landon, Greenwood, Stamp, and Wynn, 1966) .
The best way to demonstrate GH deficiency is probably by the plasma GH response to insulininduced hypoglycaemia (Roth, Glick, Yalow, and Berson, 1963) N-retention during a short HGH treatment period is higher in hypopituitary dwarfs than in control children (Prader, Illig, Szeky, and Wagner, 1964a) . The test is time consuming and tedious but has diagnostic value (Hubble, 1966 (Hubble, , 1967 Brown et al., 1967) . In theory it should tell us whether those patients with normal stature but without GH response to hypoglycaemia really lack GH, and whether the intriguing type of dwarfism with increased plasma levels of GH (Laron, Pertzelan, and Mannheimer, 1966) is due to unresponsiveness to normal HGH, or to the production ofan abnormal and inactive form of HGH. It gives occasionally misleading values (Prader et al., 1964a; Joss, Rossi, Zahnd, and Zuppinger, 1966) , as do the other tests. An interesting point is the observation that Nretention with 10 mg. HGH Raben (Hubble, 1966 (Hubble, , 1967 Brown et al., 1967) is the same as with 2 mg. HGH Raben (Prader et al., 1964a) . This confirms the assumption that the dose response curve is asymptotic, and that 2 mg. are in or near the physiological range. In an extension of this shortterm metabolic HGH test, Prader, Zachmann, Poley, and Illig (1967a) have recently shown that the serumt--amino-N increases and the ot-amino-Nclearance decreases in hypopituitary dwarfs but not in control children. These results reflect in part an increased transport of amino acids through the cell membranes. Other parameters, like the decrease of serum urea, the increase of serum phosphorus, and the increase of urinary calcium, are not significantly different in the two groups.
The GH response to hypoglycaemia and the N response to GH are generally regarded as fairly good tests for distinguishing hypopituitary from nonhypopituitary dwarfs. This cannot be said for the insulin tolerance test: in hypopituitarisiufthis test frequently but not always reveals increased sensitivity of plasma glucose to insulin, or more strictly, a decreased responsiveness of plasma glucose to insulin-induced hypoglycaemia, i.e. a retarded return of plasma glucose towards fasting values (Fraser, Albright, and Smith, 1941) . Since insulin should be given intravenously, there is some danger of severe hypoglycaemia, requiring close observation of the patient and intravenous glucose if serious symptoms develop. In the hands of some investigators this test, or a modification of it, has proved a useful screening test for recognizing GH deficiency (Prader et al., 1964a; Trygstad, 1965) , while others find mostly normal results in patients with GH deficiency (Hubble, 1967; Stinmler and Brown, 1967; Clayton et al., 1967) . It may be that hypoglycaemia unresponsiveness is only found when GH and cortisol are lacking simultaneously. This hypothesis is supported by the normal results obtained on applying this test to patients with isolated ACTH deficiency (Odell, 1966) , to patients with Addison's disease that are DOC treated and are well nourished (Fajans, 1961) , and to patients with GH deficiency but with normal or increased cortisol response to insulin-induced hypoglycaemia (Stinumler and Brown, 1967) . In hypopituitary dwarfs, nonresponsiveness to hypoglycaemia can be corrected by one injection of HGH Raben 2 mg./m.2, a presumably physiological dose (Prader et al., 1967b) .
Another diagnostic test proposed is the growth response to long-term treament with HGH. In hypopituitary dwarfs there is a sharp increase in growth velocity from pretreatment values of 1-4 cm. per year to values of 5-12 cm. during the first year of treatment (Raben, 1962 (Raben, , 1965 Soyka et al., 1964; Prader et al., 1964a; Wright, Brasel, Aceto, Finkelstein, Kenny, Spaulding, and Blizzard, 1965; Seip and Trygstad, 1966; Prader, Zachmann, Poley, Illig, and SzEky, 1967c; Mason and Tanner, 1967) , whereas no such acceleration has been observed in non-hypopituitary dwarfs. This test is unfortunately unreliable because of the frequent development of HGH antibodies (Trafford, Lillicrap, and Lessof, 1963; Prader, Wagner, Szeky, Illig, Touber, and Maingay, 1964b; Parker, Mariz, and Daughaday, 1964) . The development of antibodies during the first months of treatment in sufficient concentration to block the effect of supposedly physiological amounts of HGH has been observed in 8 out of 19 patients (Prader et al., 1967c ) treated with HGH Raben, and in at least one patient treated with HGH Li (Frasier and Smith, 1966) . The antibodies have always appeared during the first 6-9 months of treatment and never later. Since normal HGH should not stimulate the development of antibodies in man, it seems likely that certain extraction and lyophylization procedures alter the HGH molecule, making it antigenic without affecting its biological activity. In this connexion it is interesting to note that growth resistance suggesting GH suppressing antibodies has not been observed in the 12 patients treated with HGH Roos (Seip and Trygstad, 1966 
